UltraSight
PrivateLast Round
Series B
Extension
Sep 23, 2026
Total Funding Raised
$15M
Momentum
Top 1%
of companies Caplight tracks
Company Overview
UltraSight is a health tech company that provides an AI-powered software platform to guide medical professionals in acquiring cardiac ultrasound images.
Sector
Healthcare & Life Sciences
Verticals
Medical AI, Medical Imaging, Medical Devices, Computer Vision
Business Model
B2B
Customer Profile
Subscription SaaS, Services & Consulting
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
UltraSight Comparables
Compare UltraSight with similar companies based on industry and business-model similarity.
UltraSight Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B Extension | Sep 23, 2026 | ||||
| Series B | May 11, 2021 | ||||
| Series A | Mar 19, 2019 |
Key People
Founding team and executive leadership
UltraSight Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Weizmann Institute of Science | Series B |
| ARC Innovation Center | Seed |
| Connecticut Innovations | Series B Extension |
| MedTech Innovator | Seed |
| Deep Insight | Series B Extension |
| Star51 Capital | Series B Extension |
| eHealth Ventures | Series B Extension |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 23, 2026
$24M round led by ALIVE Israel HealthTech Fund.
- Mar 3, 2026
Presented at the 2026 Technology and Heart Failure Therapeutics (THT) Conference.
Recent news
Latest coverage and updates
- is_developingSep 23, 2026
UltraSight Inc. is building an AI-guided cardiac ultrasound workflow for hospitals with imaging hardware but limited specialized acquisition capacity, helping trained medical professionals collect focused echocardiography views while qualified clinicians retain responsibility for interpretation and patient care.
- receives_financingSep 23, 2026
On Sep 23rd '26 in Massachusetts, UltraSight Inc. announces it has raised $24M in Series B2 financing led by Alive HealthTech Growth Fund, with participation from Deep Insight, Star51 Capital, Connecticut Innovations, eHealth Ventures, Mayo Clinic Ventures, NYU and Iron Nation, to expand in the United States, develop new cardiac workflows and support strategic collaborations.
UltraSight Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about UltraSight's valuation, stock price, and market status.
Is UltraSight a public or private company?
UltraSight is a private company.
What is the current stock price of UltraSight?
UltraSight is a private company, so its shares have no public market price. Caplight tracks UltraSight's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is UltraSight worth (valuation)?
Valuation information for UltraSight is not publicly available.
Can I buy UltraSight stock?
UltraSight shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was UltraSight's last funding round?
UltraSight's most recent funding round was Series B Extension on September 23, 2026.
Who are the main investors in UltraSight?
Key investors in UltraSight include Weizmann Institute of Science, ALIVE Israel HealthTech Fund.
Will UltraSight IPO soon?
No public IPO plans have been announced for UltraSight.
How can I track UltraSight secondary market activity?
Caplight tracks bids, offers, and trades in UltraSight's shares on secondary markets.